

Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Published date: Dec. 13, 2019

Technology description

Title

Novel Modulators of Melanocortin Receptors for the Treatment of Depression and Anxiety

Invention

The invention is the use of the melanocortin 5 receptor (MC5R) ligand to treat depressive and anxiety disorders. MC5R antagonism is the proposed mechanism of action.

Background

Depression and anxiety often have similar treatment, but experiencing the full effects of current pharmacotherapy can range from weeks to months. Antidepressants and anxiolytics are associated with a number of side effects including an increased risk of suicidal thoughts in those taking antidepressants. Therefore, a novel pathway is needed for rapid onset with minimal side effects.

Application area

Pharmaceutical companies

Advantages

Provides a treatment for depressive and anxiety disorders

Institution

[University of Arizona](#)

Inventors

[Victor Hruby](#)

Regents Professor Emeritus
Chemistry & Biochemistry

[Minying Cai](#)

Research Professor
Chemistry and Biochemistry

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com